The amphibian tetradecapeptide, bombesin (BBS) has been shown to stimulate insulin secretion both in vivo and by pancreatic islet cells in vitro. To determine whether BBS can act directly on pancreatic (3 cells, we examined its effects on insulin secretion by HIT-T15 cells (HIT cells), a clonal islet cell line. Addition of 100 nM BBS to HIT cells stimulated insulin release 25-fold within 30 sec. The rapid stimulatory effect of BBS on insulin release was short-lived: the secretory rate returned to basal levels after 90 min of BBS treatment. The decrease in the rate of insulin release in the continued presence of BBS was due not to depletion of intracellular insulin stores but to specific desensitization to this peptide. Stimulation of insulin secretion by BBS was dose dependent with an ED.o value (0.51 ± 0.15 nM) similar to the concentration of BBS-like immunoreactive material in rat plasma. Five BBS analogs, including porcine gastrin-releasing peptide, were as powerful as BBS in stimulating insulin release. The relative potencies of the analogs tested indicated that the COOH-terminal octapeptide sequence in BBS was sufficient for stimulation of release. In contrast, 14 peptides structurally unrelated to BBS did not alter insulin secretion. BBS action was synergistic with that of glucagon; insulin secretion in the presence of maximal concentrations of both peptides was greater than the additive effects of the two peptides added individually. Somatostatin inhibited BBS-stimulated release by 69 ± 1% with an IDso value of 3.2 ± 0.3 nM. These results show that BBS stimulation of insulin secretion by a clonal pancreatic cell line closely parallels its effects in vivo and support the hypothesis that BBS stimulates insulin secretion by a direct effect on the pancreatic j cell. The clonal HIT cell line provides a homogeneous cell preparation amenable for studies on the biochemical mechanisms of BBS action in the endocrine pancreas.
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Bombesin (BBS), a tetradecapeptide originally isolated from the skin of the frog Bombina bombina (1) , is one of a group of amphibian peptides with homologous counterparts in mammalian brain and gut (2) (3) (4) (5) (6) (7) (8) . BBS modulates many behavioral, metabolic, and endocrine processes in mammals when introduced into the central nervous system or the blood stream (4, 6, 9) . These processes include regulation of body temperature, food and water intake, blood glucose levels, and the release of pituitary, pancreatic, and gut hormones. Therefore, endogenous BBS-like peptides have been proposed to play a role in the maintenance of metabolic homeostasis (4) .
In this study, we have focused on the effect of BBS on hormone secretion by the endocrine pancreas. Intravenous infusion of BBS in humans and dogs causes an increase in the plasma concentrations of both insulin and glucagon and lowers blood glucose levels (10) (11) (12) (13) (14) . In vitro, BBS stimulates the secretion of insulin and glucagon by perfused dog pancreas (15, 16) , whereas it has been shown to either stimulate (17) or inhibit insulin release by isolated rat pancreas (18 (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) , cholecystokinin octapeptide, oxytocin, vasopressin, growth-hormone releasing factor(1-44), secretin, and vasoactive intestinal peptide were purchased from Peninsula Laboratories (San Carlos, CA). Somatostatin, calcitonin, substance P, and neurotensin were purchased from Beckman.
[Leu]Enkephalin was obtained from Bachem Fine Chemicals (Torrance, CA). Thyrotropin-releasing hormone was provided by Abbott (North Chicago, IL). Culture medium, horse serum, and fetal calf serum were purchased from GIBCO, and plastic culture dishes were from Falcon. IgGsorb (Staphylococcus aureus protein A) was purchased from Enzyme Center (Boston). Glucagon, melatonin, phenylmethylsulfonyl fluoride, and iodoacetamide were purchased from Sigma. Monocomponent porcine insulin (lot no. 615-07J-256) and HIT cells were generous gifts from Eli Lilly.
Cell Culture. The establishment and properties of the HIT cell line have been described (19) . After several months of propagation in our laboratory, the cells became more flattened and more tightly adherent to culture dishes. The flattened cells continued to secrete insulin and their responses to glucagon and somatostatin were similar to that described by Santerre et al. (19) (24) . The limit of assay sensitivity was 15 pg of insulin per 0.1 ml of sample buffer. HIT cell (hamster) insulin and porcine insulin gave parallel displacement curves for inhibition of iodinated antigen binding. The intra-assay variability was ±5% and inter-assay variation was ±27%.
Measurement of Insulin Secretion. To determine the effect of BBS and other neuropeptides on insulin secretion, replicate dishes were washed twice with a Hepes-buffered salt solution containing 118 mM NaCl/4.6 mM KCl/0.5 mM CaCl2/1 mM MgCl2/10 mM glucose/5 mM Hepes/0.1% NaHCO3/0.1% bovine serum albumin, pH 7.2. Subsequently, 1 ml of Hepes-buffered salt solution, preequilibrated at 
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370C in 5% C02/95% air and containing the appropriate concentration of peptide, was added. The cultures were then incubated for the desired time at 370C in humidified 5% C02/95% air. For the short time course experiment shown in Fig. lA, cells were washed with buffer then incubated in Hepes-buffered salt solution without NaHCO3 (pH 7.2) at 370C in ambient atmosphere. At the end of each incubation, the buffers were collected, floating cells were removed by centrifugation, and the supernatants were stored at -20'C for the subsequent determination of insulin concentration by RIA.
To determine the extent of insulin degradation by HIT cells, we measured the recovery of exogenous [1251]insulin and nonradiolabeled insulin from the incubation buffers by precipitation with 10% trichloroacetic acid and by RIA, respectively. After incubation with HIT cells for 60 min at 370C, [1251] insulin (0.15-6 ng/ml) was degraded only 21 ± 2% and nonradiolabeled insulin (100 ng/ml) was degraded only 25 ± 12%. Furthermore, the addition of 100 nM BBS did not alter the stability of either radiolabeled or nonradioactive insulin (data not shown). Therefore, the 5-to 25-fold increase in insulin accumulation induced by BBS cannot be due to inhibition of insulin degradation in the medium. Measurement of Intracellular Insulin. For determination of intracellular insulin levels, HIT cells were extracted into 5 M acetic acid containing bovine serum albumin (5 mg/ml)/ phenylmethylsulfonyl fluoride (0.3 mg/ml)/iodoacetamide (0.3 mg/ml). Samples were snap-frozen and thawed 3 times and then extracted at 40C for 16-20 hr. Extracts were centrifuged and the supernatants were lyophilized. The lyophilized samples were dissolved in a buffer of 10 mM NaH2PO4/1 mM Na2EDTA/0.1% Triton X-100/phenylmethylsulfonyl fluoride (0.3 mg/ml)/iodoacetamide (0.3 mg/ml), pH 7.6. Insulin concentrations in the extracts were determined by RIA.
RESULTS
The Effect of BBS on Insulin Secretion. The data in Fig. 1 show the effect of 100 nM BBS on insulin secretion by HIT cells. The stimulatory effect of BBS was very rapid; within 30 sec BBS caused a 25-fold increase in insulin release (Fig.  LA) . Thereafter, the secretory rate decreased and returned to basal levels by 90 min (Fig. 1B) . The lack of a prolonged stimulatory effect of BBS on secretion could have been due to depletion of intracellular insulin stores. However, during a 60-min incubation at 37°C, 100 nM BBS caused the release of only 1.04 ± 0.07% (mean ± range; n = 2) of intracellular insulin. Furthermore, there was no detectable difference in the insulin content of untreated and BBS-treated cells (data not shown). Therefore, stimulation of insulin release by BBS does not deplete intracellular stores. The explanation for the transient nature of the response to BBS is discussed below.
The concentration dependence for the stimulation of insulin release by BBS is shown in Fig. 2 To analyze the structural requirements for biological activity in BBS-like peptides, we tested five BBS analogs shown in Table 2. [Tyr4]BBS, which has a tyrosine instead of a leucine at position four, is the synthetic analog used for radiolabeling in receptor-binding studies (25, 26) . Litorin and ranatensin, peptides originally isolated from amphibian skin (6) , both contain the last eight COOH-terminal amino acids of BBS with a penultimate leucine for phenylalanine substitution. GRP, a mammalian BBS analog isolated from porcine gut, has the same COOH-terminal decapeptide sequence as Table 3 show that the four short peptides were equipotent with BBS. However, BBS was 4-fold more potent than GRP, the NH2-terminal extended analog (Table 3 ). The relative potencies of these peptides indicate that the COOH-terminal octapeptide sequence in BBS is sufficient for stimulation of insulin secretion.
The Effect of Somatostatin and Glucagon on BBS-Stimulated Secretion. Both in vivo and in pancreatic islets in vitro, glucagon stimulates insulin secretion (27) , whereas somatostatin inhibits it (28) . Because HIT cells respond in the expected manner to these two peptides (19) , we investigated the effect of glucagon and somatostatin on the stimulatory action of BBS. A maximal concentration of BBS (100 nM) increased insulin release 10-fold, whereas, in the same experiment, glucagon (1 ,uM) caused a 6-fold increase ( Table 4 ). The simultaneous addition of glucagon and BBS at maximal concentrations resulted in a 40-fold stimulation of insulin secretion (Table 4 ). In three independent experiments, the effect of glucagon plus BBS was 1.7 + 0.3-fold greater than the additive effect of the two peptides alone. Therefore, BBS and glucagon act synergistically to stimulate insulin release.
Although 100 nM somatostatin had no effect on basal insulin secretion, it inhibited the stimulatory effect of BBS by 71% (Table 4) . In four experiments, this concentration of somatostatin inhibited BBS-stimulted insulin release by 69 ± 1% (mean ± SEM). Fig. 3 shows that the inhibitory effect of somatostatin was dose dependent: the ID50 for somatostatin in two experiments was 3.2 ± 0.3 nM (mean ± range).
We have characterized specific, high-affinity receptors for
BBS in HIT cells and have shown that the binding of [125I1
Tyr4]BBS is not affected by either somatostatin or glucagon (unpublished observations). Therefore, the modulatory ef- GRP (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) pGlu-Gln-Arg-Leu-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-MetNH2 pGlu-Gln-Arg-TyE-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-MetNH2 fects of somatostatin and glucagon on BBS action must be mediated by independent receptors. BBS-Induced Desensitization. The observation that BBS had a transient effect on insulin release (see Fig. 1 ) without depleting intracellular insulin stores suggested that HIT cells desensitize to the stimulatory effect of BBS. To test this hypothesis, cells were incubated for 2 hr in the presence or absence of 100 nM BBS and then challenged in fresh buffer with three different secretagogues. During the first incubation, 100 nM BBS caused a 10-fold increase in insulin secretion (Fig. 4A) . However, cells exposed to BBS in the first incubation did not respond to subsequent treatment with BBS (Fig. 4B) . In contrast, cells preincubated with BBS did respond to glucagon and a high concentration of K+ with increased insulin release (Fig. 4B) . These data show that BBS induces specific desensitization in HIT cells.
DISCUSSION
BBS is a potent stimulator of insulin secretion when infused intravenously into either humans or experimental animals (10) (11) (12) (13) (14) . In addition, BBS-like peptides are present in peptidergic neurons of the mammalian pancreas, and electrical stimulation of the splanchnic nerve has been shown to increase BBS levels in peripheral plasma to concentrations sufficient to stimulate insulin release (29, 30) . These results strongly suggest that BBS-like peptides play an important role in the physiological control of insulin secretion.
The data presented here show that BBS directly stimulates at the same low concentrations that stimulate insulin secretion in perfused dog pancreas (15, 16) and increase plasma insulin levels in dogs and humans (10, 14) . In all systems, the response to BBS is rapid and transient. Infusion of BBS in dogs and humans produced a maximal stimulation of insulin secretion within 5 to 15 min followed by a decrease in insulin levels during continued infusion of the peptide (11) (12) (13) (14) . Similarly, in perfused isolated canine pancreas, stimulation of insulin release was maximal after 2 min and decreased thereafter (15, 16) . In HIT cells, a 25-fold stimulation of insulin release occurred 30 sec after the addition of BBS and the secretory rate subsequently decreased to the basal rate. As in vivo (13) , somatostatin inhibited the stimulatory effect of BBS in HIT cells. Finally, a mammalian BBS-like peptide, GRP, increased insulin release both when infused intravenously into dogs (14) and when added to HIT cells. These observations suggest that the effects of BBS-like peptides on insulin secretion in vivo are due to direct action on 3 cells.
To determine the structural requirements for BBS action, we compared the potencies of several BBS analogs to stimulate insulin secretion by HIT cells. Our data indicate that the COOH-terminal octapeptide sequence in BBS is sufficient for potent stimulation. Of additional interest is the observation that porcine GRP was less potent than the amphibian peptide BBS. Similar results have been observed in other systems. For example, when injected intracisternally into rats, BBS is more potent than GRP in producing hypothermia and hyperglycemia (31) and in causing inhibition of gastric acid secretion and stimulation of gastrin release (32) .
Furthermore, BBS has been shown to bind to receptors in a rat pituitary cell line with a 3-fold higher apparent affinity than does GRP (26) . The greater potency of the amphibian peptide BBS than its mammalian analog probably reflects (3, (6) (7) (8) . Recently, three biologically active BBS-like peptides have been purified from canine intestine (5) . These peptides share a common COOHterminal sequence that has substantial homology with both porcine GRP and amphibian BBS. The observation that BBS and GRP (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) are more potent than GRP in some target cells (refs. 31 and 32; Table 3) indicates that the COOH-terminal fragments of endogenous BBS-like peptides are physiologically more potent than their NH2-terminal extended counterparts. However, diverse target tissues do show differential sensitivity to various BBS-like peptides (4, 6, 7). Molecular heterogeneity and differential cellular responsiveness to active forms have also been reported for the neuropeptides somatostatin, cholecystokinin, and gastrin (28, 33, 34) . Further studies are clearly warranted to determine the relative importance of the different forms of mammalian BBS in the various biological actions of this peptide.
Both in vivo and in perfused pancreas the stimulatory effect of BBS on insulin secretion is transient (11) (12) (13) (14) (15) (16) . Similarly, in HIT cells the time course for BBS-stimulated insulin secretion shows a return to the basal secretory rate by 90 min in the continued presence of the peptide. This decrease in secretory rate is not due to a significant decrement in intracellular insulin, but rather to specific desensitization of the cellular response to BBS. Desensitization to BBS has also been observed in dispersed pancreatic acinar cells (35, 36) . Since BBS-induced desensitization and resensitization in acinar cells occur in the absence of protein synthesis, BBS receptors must be able to cycle between active and inactive states. However, the mechanism by which BBS desensitization occurs remains to be determined.
An interesting result obtained in our study was the synergistic effect of BBS and glucagon on insulin secretion. Glucagon elicits its biological effects by increasing intracellular cAMP levels in target cells (37) . The intracellular mechanism of BBS action has been most thoroughly investigated in the exocrine pancreas where its effects appear not to be mediated by cAMP (38) (39) (40) . In pancreatic exocrine cells BBS has been shown to modulate membrane potential, calcium efflux, cGMP accumulation, and phosphatidylinositol turnover (38) (39) (40) 
